Spanish CDMO, Idifarma, Begins Seventh Project with Biotechnology Company

Idifarma, a contract development and manufacturing organisation (CDMO), based in Spain, has announced the commencement of the seventh project with Palobiofarma-a Spanish biotechnology company.

As per the terms of the agreement, Idifarma will take on the complete pharmaceutical development of Palobiofarma’s novel candidate, PBF-2897, including drug formulation, development of analytical methods and GMP manufacturing for clinical trials. The new drug candidate is a potent, non-blood–brain-barrier permeable, adenosine A1 receptor antagonist that will be used as an oral treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease. It is currently in Phase II clinical trials and is expected to complete next year.

“Palobiofarma and Idifarma have had a strong relationship for most of the decade, successfully working together on six projects since 2012, and this latest project extends and strengthens that relationship,” said Luis Oquiñena, general manager and co-founder of Idifarma, in an Oct. 26, 2018 press release. “With this project, Palobiofarma will have continued access to Idifarma's specialist capabilities and top-class manufacturing site as well as providing them with a trustworthy and flexible partner for development of their novel drugs and manufacturing and packaging for clinical trials.”

Co-founder and chief executive officer of Palobiofarma Julio Castro added, “This latest agreement with Idifarma is testament to the successful collaboration between the two companies so far. We value the commitment, seriousness and quality of Idifarma as one of our best collaborators. Without them it would not have been possible for Palobiofarma to successfully bring seven different novel drugs into clinical development.”

Source: Idifarma